Back to top
more

G1 THERAPEUTICS (GTHX)

(Delayed Data from NSDQ)

$21.61 USD

21.61
229,042

+0.72 (3.45%)

Updated May 3, 2019 04:00 PM ET

After-Market: $21.60 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.93%
2Buy18.12%
3Hold10.10%
4Sell5.65%
5Strong Sell2.94%
S&P50011.36%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Brokerage Reports

[GTHX]

Reports for Purchase

Showing records 121 - 140 ( 361 total )

Industry: Medical - Biomedical and Genetics

Record: 121

01/13/2022

Daily Note

Pages: 8

MORNING CALL

Provider: WEDBUSH SECURITIES INC.

Analyst: Research Department

Price: 12.50

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 122

01/12/2022

Company Report

Pages: 6

Cosela Looks to Keep Cooking

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 12.50

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 123

01/11/2022

Daily Note

Pages: 4

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 5.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 124

01/10/2022

Company Report

Pages: 6

Early Data from Three Trials Slated During Second Half of This Year

Provider: Roth Capital Partners, Inc.

Analyst: BUTLER T

Price: 12.50

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 125

12/17/2021

Daily Note

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 5.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 126

12/17/2021

Daily Note

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 5.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 127

12/17/2021

Company Report

Pages: 7

Additional Hires Announced for Cosela Sales Force Amid Transition Away From Co-Promotion

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 12.50

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 128

12/16/2021

Company Report

Pages: 7

Cosela Ringing in ''22 By Getting Rid of Ringers

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 12.50

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 129

12/16/2021

Company Report

Pages: 7

G1 Going It Alone to Commercialize COSELA

Provider: Roth Capital Partners, Inc.

Analyst: BUTLER T

Price: 12.50

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 130

12/01/2021

Daily Note

Pages: 8

Biotechnology- Catalysts from Our Coverage Universe: YE2021 and Beyond

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 12.50

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 131

12/01/2021

Daily Note

Pages: 3

New Phase 2 Studies of Cosela in TNBC Initiated

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 5.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 132

11/04/2021

Company Report

Pages: 6

3Q21 Results; Revenues Lower Than Expected, Two Registrational Studies to Read Out in 2023; Lowering PT to $71

Provider: H.C. Wainwright & Co., Inc.

Analyst: WHITE E

Price: 12.50

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 133

11/04/2021

Daily Note

Pages: 8

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Analyst: Research Department

Price: 12.50

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 134

11/03/2021

Company Report

Pages: 6

3Q21: Efforts Are Underway to Increase Demand for COSELA. PT to $54

Provider: Roth Capital Partners, Inc.

Analyst: BUTLER T

Price: 12.50

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 135

11/03/2021

Company Report

Pages: 7

COSELA Looking to Get Back Into the Batter''s Box in ''22

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 12.50

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 136

11/01/2021

Industry Report

Pages: 12

HEALTHCARE- The Week Ahead in Life Sciences

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 12.50

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 137

10/14/2021

Company Report

Pages: 6

COSELA Still A Steal

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 12.50

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 138

10/08/2021

Daily Note

Pages: 9

MORNING CALL

Provider: WEDBUSH SECURITIES INC.

Analyst: Research Department

Price: 12.50

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 139

10/07/2021

Daily Note

Pages: 4

Cosela Reduces Chemo-Induced Co-Morbidities

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 5.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 140

09/28/2021

Company Report

Pages: 10

ValuEngine Detailed Valuation Report for GTHX

Provider: ValuEngine, Inc

Analyst: Research Department

Price: 25.00

Research Provided by a Third Party